Systemic sclerosis & Raynaud's
Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis–Related Interstitial Lung Disease
Authors' conclusion
Severity of reflux symptoms as measured by an SSc-specific questionnaire was independently associated with the change in the radiographic extent of ILD and fibrosis over 2 years in patients with SSc-ILD. Two objective measures of esophageal dilation were not associated with radiographic progression of ILD
Study context
- Population
- Participants of the Scleroderma Lung Study II (mycophenolate vs cyclophosphamide for SSc-ILD)
- Participants
- 141 participants
- Primary endpoint
- Progression of SSc-ILD by radiologic quantitative ILD (quantitative interstitial lung disease (QILD)) and quantitative lung fibrosis (QLF) in the lobe of maximum involvement (LM)
- Follow-up
- 2 years
Methodological detailsunivariate and multivariable linear regression, adjusted for treatment arm, baseline ILD severity and proton-pump inhibitor use
- Univariate and multivariable linear regression
- Adjusted for treatment arm, baseline ILD severity and proton-pump inhibitor use
Primary result
As reported in the abstract
Association of reflux symptoms and esophageal dilation with change in QLF-LM and QILD-LM
Baseline mean patient-reported reflux score (moderate reflux)
0.57
Baseline mean maximal esophageal diameter (mm)
22
Baseline mean maximal esophageal area (mm²)
242
Original publication
Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis–Related Interstitial Lung Disease. Arthritis Care Res (Hoboken). Published 7 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →